Full Text
PCN152 - COST EFFECTIVENESS OF ALECTINIB IN THE FIRST LINE TREATMENT OF ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN TURKEY

Abstract

Authors

E. Öksüz S. Malhan L. Yanik E. Koc E. Erdogan-Ciftci B. Guler P. Orfanos

Back to Volume 21, Supplemental S3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×